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ABSTRACT

Neisseria gonorrhoeae (Ng) is a sexually transmitted bacterium that infects human
reproductive mucosal surfaces. Due to the risk of complications in untreated cases and
evolving antibiotic resistance, a prophylactic vaccine is critical for preventing infection.
There are four Ng outer-membrane proteins that contribute to Ng survival and resistance:
PorB, BamA, TbpA, and MtrE. Each protein contains surface-exposed loops that are targets
of bactericidal antibodies. Vaccines were developed by displaying Ng epitopes on the surface
of bacteriophage virus-like particles (VLP). VLPs are immunogenic, multivalent, selfassembling complexes composed of viral structural proteins. Antigenic peptide sequences
can be displayed on the surface of VLPs via chemical conjugation or genetic insertion
(recombination) into the structural protein sequence.
Thirty-seven VLP vaccines displaying Ng epitopes were constructed. Mice were
vaccinated with VLPs, and antibody responses were measured. Immunogenicity studies
demonstrated that the majority of VLPs elicited high-titer, peptide-specific antibody
responses that may neutralize whole pathogen.
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CHAPTER 1
INTRODUCTION
The Fundamentals of Vaccination
Infectious diseases have plagued the human species for generations, but modern
medicine has facilitated prevention and elimination of infections that can cause significant
illness or death. Critical countermeasures in the fight against infectious agents are vaccines,
which are defined by the Oxford Dictionary as “[substances] used to stimulate the production
of antibodies and provide immunity against one or several diseases, prepared from the
causative agent of a disease, its products, or a synthetic substitute, treated to act as an antigen
without inducing the disease”.
The immune system is divided into two operational arms – the innate immune system
and the adaptive immune system. While the innate immune system provides immediate and
non-specific protection against foreign invaders, the adaptive immune system relies on an
elegant but slow process of specific antigen recognition to facilitate both cellular and
humoral (antibody-mediated) immune responses. Key players in the adaptive immune
response that mediate targeted defenses are antibodies, which are produced by B-cells. Bcells are initially armed with membrane-bound antigen receptors (IgM and IgD) that are
generated randomly and can recognize diverse antigens. Upon engagement of antigen, Bcells, with the help of T-cells, will proliferate within secondary lymphoid organs. Clonal
expansion of B-cells promotes the production of high numbers of one specific B-cell
receptor. When B-cells are activated they begin to produce a soluble form of the antigen
receptor, termed an “antibody”, that will circulate and bind with high affinity to the invading
pathogenic agent. B-cells also undergo isotype switching (Stavnezer & Amemiya, 2004),
leading to the production of different forms of the antibody molecule (such as IgG, IgA, and
IgE) with different effector functions. B-cells can differentiate into memory B-cells, which
circulate through the lymphoid organs in anticipation of future exposure to the same
pathogen. Memory B-cells are critical to the sustained, protective response of antibodies
against a pathogen upon repeated exposure.
Antibodies possess an array of protective and defensive effector functions (Abbas et
al., 2018b). When an antibody encounters antigen, it will bind the antigen, initiating a
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cascade of immunological events. Direct antibody binding may neutralize the pathogen or its
toxin, preventing the pathogen from infecting cells or causing cellular damage via steric
hinderance. Further, antibodies bound to pathogens can opsonize and enhance phagocytic
uptake of the pathogen by cells of the innate immune system, such as macrophages, enabling
better pathogen clearance and antigen presentation. Natural killer cells that recognize bound
antibodies will initiate apoptosis of the cell to which the antibody is bound in a process
known as antibody-dependent cellular cytotoxicity. Finally, antibodies can activate the
complement system, which can enhance phagocytosis and microbe destruction.
Antibody production is a foundation for vaccine efficacy. As stated, vaccines are
substances that present as some form of antigen to which the body may develop an immune
response. Without engaging the immune system in a full-blown attack, vaccines prime the
immune system so that it can respond rapidly to future infections. Specifically, vaccines
prompt immediate production of antibodies as well as the differentiation of memory B-cells
that will persist and protect the vaccinated individual. In this way, vaccines induce active
immunity via a mechanism similar to natural infection (Baxter, 2007).

The History of Vaccines:
The concept of a vaccination materialized in the early 18th century. To combat the
rampant smallpox epidemic in Europe, “variolation” was performed, after it was noted that
patients who survived smallpox were resistant to future infection. Variolation was introduced
to Europe in the 1720s and involved creating a small wound in the skin, followed by
insertion of infectious material into the wound. Inoculation with material taken from a fresh
pustule of a person infected with smallpox prevented infection in variolated persons. Edward
Jenner, who had been variolated in his childhood, noticed that infection with cow pox was
protective against smallpox as well, and coined the term “vaccination” from the Latin word
“vacca”, meaning cow (Riedel, 2005). Jenner’s initial smallpox vaccination consisted of
material from cowpox pustules applied with a lancet to a part of the upper arm that had been
scratched. Importantly, this vaccination technique and the subsequent success of the
vaccination required live virus to be present in the cowpox pustules, having produced active
infection in the source cow and a mild infection in the vaccinated person (Belongia &
Naleway, 2003). Smallpox has now been eradicated due to successful vaccination efforts.
2

Vaccine development exploded in the late 19th and early 20th centuries. In 1884,
Louis Pasteur and Emile Roux extracted bone marrow from rabbits who had died from
rabies, set the marrow out to dry for 15 days (a form of attenuation that would later be
improved by chemical methods), and proceeded to vaccinate a child who had been bitten by a
rabid dog. The vaccine was successful in preventing rabies in the child (Geison, 1978).
Wilhelm Kolle, in 1896, heat-inactivated cholera bacilli for vaccination (Kolle & Pfeiffer,
1896). Formalin treatment of the Diphtheria toxin by AT Glenny and Barbara Hopkins in
1923 both inactivated the toxin and demonstrated that toxic products associated with
pathogenic agents could also be used to produce protection (Glenny & Hopkins, 1923).
Today, Diphtheria, Pertussis, and Tetanus toxins are all given in one composite
immunization.
Vaccine research benefitted greatly from advancements in molecular and
microbiology in the late 20th and early 21st centuries. The oral polio vaccine that was
developed by Albert Sabin in 1960 relied on cell culture techniques to grow viruses that
would then be attenuated for administration (Sabin, 1959). The MMR vaccine used to protect
against measles, mumps, and rubella, was also developed from a combination of live,
attenuated viruses (Stokes et al., 1971). In 1963, a mysterious protein body, termed the
“Australia antigen” was found to be associated with Hepatitis B infection (Bayer et al.,
1968). After repeated isolation and purification methods, a successful and safe Hepatitis B
vaccine was developed by Maurice Hilleman that relied on surface protein subunits that
encased the virus (McAleer et al., 1984).
The Center for Disease Control’s (CDC) suggested vaccine profile consists of a
variety of vaccine subtypes. Whole pathogen vaccines include the annual flu vaccine and
MMR II. The trivalent vaccine for Tetanus, Diptheria, and Pertussis is a toxoid-based
vaccine. Subunit, polysaccharide, recombinant, or conjugate vaccines that are based on
antigenic molecules expressed by pathogens include that for HPV (Rose et al., 1999; Zhai &
Tumban, 2016), Haemophilus influenzae type B (Adams et al., 1993), and Neisseria
meningitidis (Gasparini & Panatto, 2011). Additional platforms are being investigated,
including nucleic acid (Vogel & Sarver, 1995).
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The Need for a Vaccine: Neisseria gonorrhoeae
Neisseria gonorrhoeae (Ng) is a sexually and vertically transmitted, gram-negative
diplococcus bacterium that exclusively infects humans. New cases in the United States are
estimated at 820,000 per year (CDC), with 583,405 cases reported to the CDC in October
2018 (CDC, 2019). Gonorrhea is the second most common bacterial sexually transmitted
infection (STI), following Chlamydia trachomatis (NIH, 2017).
Ng colonizes human mucosal surfaces, including those of the respiratory and
reproductive tracts. Ng will attach to mucosal epithelial cells via type IV pili, opacity (Opa)
proteins, lipooligosaccharides (LOS), and porin proteins. Epithelial carcinoembryonic
antigen-related cell adhesion molecules (CEACAMs) are important receptors for Ng
attachment via Opa protein interaction (Edwards & Apicella, 2004). Ng can move through
epithelial cells via transcytosis and may replicate intracellularly (Holmes, King et al., 2008).
During epithelial invasion and colonization of the basement membrane, Ng will release a
variety of immunostimulatory molecules, including outer membrane vesicles (OMVs) that
contain Ng proteins. Recruitment of various cellular defenders, such as neutrophils and
macrophages, results in phagocytosis of bacterial cells and inflammation (Quillin & Seifert,
2018). While innate immune responses to gonococcal infection are substantial, adaptive
immune responses are minimal, and it may be hypothesized that clearance is associated with
effective innate rather than adaptive immune responses. Gonococcal infection is often
associated with a TH17 helper T-cell response, which can help recruit neutrophils for
clearance (Jerse et al., 2014). However, induction of TH17 responses may contribute to
immunosuppression, thereby dampening future adaptive responses. Additionally, Ng has
evolved a variety of immune evasion mechanisms that impair adaptive responses, as
described below.
Men who have contracted Ng are likely to experience symptoms, including a burning
sensation with urination, swollen testicles, or abnormal discharge. Specifically, a purulent
exudate that generally contains neutrophils, bacterial cells, and sloughed epithelial cells, is
characteristic of infection. While men may present with symptoms 1-14 days after infection,
women can be completely asymptomatic or mistake gonococcal infection with a nonspecific
bladder or vaginal infection, due to the similarity in symptoms (Farley et al., 2003).
Approximately 80% of women will not experience any symptoms during infection (Little,
4

2006). Purulent exudate that is characteristic of gonococcal infection is more easily
detectable and diagnosable in males, perhaps contributing to more noticeable infections in
males (Quillin & Seifert, 2018).
Untreated infection, potentially due to lack of symptoms, is especially problematic, as
it may lead to urethritis, cervicitis, or pelvic inflammatory disease (PID). Uncontrolled
swelling and inflammation associated with PID can cause infertility or increase the risk of an
ectopic pregnancy in women. Ng infection can become disseminated and cause systemic
sepsis, chronic joint infection, endocarditis, meningitis, and pneumonia (Rechner et al., 2007;
Walker & Sweet, 2011). Additionally, vaginally-delivered babies of infected mothers are at
risk of conjunctivitis and blindness (Walker & Sweet, 2011).
The current treatment for Ng infection, as recommended by the CDC (2015), is a dual
therapy of injected ceftriaxone and oral azithromycin. Unfortunately, treatment is
complicated by Ng’s resistance to other antibiotics, including penicillin, tetracycline, and
fluoroquinolones (CDC, 2019). Although dual therapy is fairly effective, there is mounting
evidence for emergence of antibiotic resistant strains of Ng (Chisholm et al., 2009; Palmer et
al., 2008; Starnino et al., 2009; Yin et al., 2018). Due to evolving antibiotic resistance as well
as the risk of more severe complications in untreated cases, a prophylactic vaccine is critical
for preventing infection in susceptible populations.
Unfortunately, clearance of infection and vaccine development have been impeded by a
variety of Ng characteristics. Ng LOS (which are common ligands for toll-like receptors), the
opacity family of outer membrane proteins (Opa), and pilus protein (Cahoon & Seifert, 2011)
[(Opa and pilus proteins play critical roles in invasion of the mucosal epithelium during
invasion (Mestecky et al., 2015)] are common immune targets, but are highly antigenically
variable. Therefore, it is challenging to generate broadly effective vaccines against Ng that
target these surface components. Additionally, natural infection and whole-pathogen based
vaccine methods generally do not produce strong immunological responses (Greenberg et al.,
1974; Hedges et al., 1999; Jerse et al., 2014), prompting extensive searches for other
immunogenic Ng antigens and novel strategies for developing vaccines which target these
antigens.
Ng has evolved mechanisms to circumvent effector immune responses during infection,
which explain poor adaptive immune responses during natural infection and are also
5

problematic for vaccine development. These immune evasion strategies impact the four main
immune effector functions for bacterial clearance: phagocytosis/opsonization, complementmediated lysis, cell-mediated immunity, and the production of bactericidal antibodies.
Cells of the innate immune system survey the body for infection and take up infectious
agents for destruction via phagocytosis. Simply, phagocytes ingest either free or antibodybound pathogen, and the pathogen will then be digested in the lysosome. Part of the pathogen
may be presented on the phagocytes’ surface for adaptive immune system activation.
Variable expression of Opa proteins on the surface of Ng may not bind to neutrophil
CEACAMs, limiting uptake of the pathogen (Sintsova et al., 2015). Ng can also survive
inside the phagosomes of macrophages and neutrophils, and even promote apoptosis of
macrophages via the NLRP3 inflammasome pathway (Château & Seifert, 2016; Johnson &
Criss, 2013).
All three complement pathways (classical, alternative, and lectin) culminate in the
formation of membrane attack complexes (MACs) on the surface of large pathogens which
effectively destroy the integrity of the pathogen’s cell wall or membrane via the generation of
large pores (Abbas et al., 2018b). Complement-mediated killing is deterred by Ng via
improper deposition of complement factors C5b-C9, resulting in faulty insertion of the MAC,
masking of target sites for antibody binding, or direct binding of complement factors (C4b
and factor H), all via the outer membrane porin (Por) proteins (Hill et al., 2016).
Cell-mediated immunity includes the activation of antigen-specific cytotoxic T cells,
which are activated when presented with antigen by macrophages or dendritic cells. Ng is
antigenically variable, and thus presented antigen may not mirror antigen expressed by
replicating pathogen. Ng induces a Th-17 T-cell response, which can suppress Th-1 or Th-2
T-cell responses that would also promote immunologic memory (Lenz & Dillard, 2018).
Additionally, Opa proteins expressed by Ng can suppress T cell activation by binding T-cell
CEACAM receptors and inducing an inhibitory intracellular cascade (Boulton & GrayOwen, 2002). Ng infection also triggers the expression of inhibitory proteins on the surface
of dendritic cells (PD-L1 & PD-L2) that can further limit T-cell expansion (Zhu et al., 2012).
Ng expresses reduction modifiable protein (Rmp), which is located immediately adjacent
to porin proteins (Figure 2) is highly conserved and promotes antibody responses.
Unfortunately, the production of bactericidal antibodies against Rmp blocks the effect of
6

bactericidal antibodies produced against outer membrane Por proteins, potentially by
interfering with complement deposition, effectively promoting serum-resistance (Plummer et
al., 1993). Additionally, antibodies directed against Rmp may sterically hinder Por
antibodies, due to the proximity of the two proteins (Edwards & Apicella, 2004).
In sum, Ng’s vast capabilities for evading the immune system render it a more difficult
target for vaccine development. However, bactericidal antibodies against other specific
surface-exposed targets may still be effective mediators for combating Ng infection. It has
been shown that an IgG targeting LOS can promote opsonophagocytosis by neutrophils
(Johnson & Criss, 2013), supporting the possibility that antibodies targeting specific Ng
antigens may effectively prevent infection.

Ng Surface Proteins: Targets for Vaccine Development
There is evidence for the generation of bactericidal antibodies against semi-conserved or
conserved outer-membrane Ng surface proteins. Mice immunized with gonococcal outer
membrane were bled for sera, and a comprehensive profiling of bactericidal antibodies
indicated a range of protein targets on the surface of Ng that could serve as vaccine
candidates (Plante et al., 2000; Rice et al., 2017; Wang et al., 2018; Zielke et al., 2016).
Among this list were four Ng surface proteins that play important roles in invasion and
infection, bacterial survival, nutrient acquisition, and antibiotic resistance: Porin B (PorB), βbarrel assembly machinery A (BamA), Transferrin binding protein A (TbpA), and Multiple
transferable resistance E (MtrE), respectively (Figures 1 & 2).
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Figure 1: Ng targets of bactericidal antibodies: A: PorB (PDB ID 3A2S, Tanabe et al., 2010); B: BamA (PDB
ID 4K3B, Noinaj et al., 2013); C: TbpA (PDB ID 3V89, Cash et al., 2015) (green) in a complex with human
transferrin (orange); D: A single subunit of the MtrE homotrimer (PDB ID 4MT0, Lei et al., 2014). Black
arrows indicate targeted extracellular loop domains within each protein. Images were generated using RCSB
PDB.
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Figure 2: Location and function of Ng protein targets

Porin proteins are the most abundantly expressed proteins in the Ng outer membrane
(Russell & Hook, 2009; Tanabe et al., 2010; Zhu, Weiyan et al., 2011). PorB is an outer
membrane, voltage-gated porin protein that plays a role in ion exchange and is required for
bacterial survival. During infection, PorB will localize to the mitochondria after secretion by
Ng, where it may promote apoptosis and further infection of host cells (Deo et al., 2018).
Additionally, PorB has been implicated in a spectrum of immune evasion mechanisms,
including interactions with the human complement system as well as interference with the
production of reactive oxygen species (ROS) by innate immune cells (Chen & Seifert, 2013).
Importantly, PorB may play a role in bacterial invasion of the mucosal epithelium
(Kühlewein et al., 2006). PorB is encoded by two alleles (P1A and P1B), which share 80%
sequence homology with one another (Carbonetti et al., 1988). PorB is a homotrimeric βbarrel with 8 surface-exposed loops that protrude from the base. While PorB boasts relatively
stable expression in contrast to the highly variable Opa and pilus proteins, there is variability
of PorB sequence between Ng strains, with the greatest variability in the loop domains.
The β-barrel assembly machinery (Bam) is responsible for the integration of β-barrel
protein species into the outer membrane of gram-negative bacteria (Leyton et al., 2015;
Noinaj et al., 2013). BamA is the outer membrane protein of the assembly machinery.
Essential for bacterial survival, BamA is also expressed in 100% of Ng isolates and its
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deletion results in loss of Ng viability (Zielke et al., 2016). BamA is a highly conserved and
antigenically stable structure with eight extracellular loops.
Iron is a requirement for all living organisms but does not exist in its free form in high
concentrations in the human body. Thus, bacterial pathogens require a mechanism by which
iron may be acquired from the environment by effectively sequestering it from host proteins.
One of the mechanisms whereby Ng sequesters iron is via the transferrin (Tf) binding protein
complex, composed of a TonB-dependent transporter, and transferrin binding proteins A
(TbpA) and B (TbpB) (Ronpirin et al., 2001). The transferrin binding complex is expressed
in 100% of clinical isolates, supporting its necessity for Ng survival (Cash et al., 2015).
TbpA is semiconserved amongst Ng isolates and can also induce bactericidal antibodies
against Ng when conjugated to Cholera toxin B subunit (Price et al., 2005). TbpA resides on
the outer membrane of the cell and contains 4 surface-exposed loops that are hypothesized to
make contact with human transferrin.
Multiple transferable resistance E (MtrE) is a component of the Ng efflux pump, which is
capable of expelling a variety of antimicrobial agents (Lei et al., 2014; Warner et al., 2007),
therefore playing a critical role in antimicrobial resistance. The Mtr property is facilitated by
the MtrC-MtrD-MtrE efflux pump system (Veal et al., 2002). Additionally, it has been
shown that an Ng strain deficient in the MtrCDE efflux pump system was cleared more
rapidly in female mice (Jerse et al., 2003), implicating the efflux pump system as a potential
virulence factor. MtrE is a homotrimer with two surface-exposed loops and an outer
membrane channel and is highly conserved amongst Ng strains.
PorB, BamA, TbpA, and MtrE all contain exposed extracellular loops, which make them
easily accessible to antigen receptors as well as potential targets of bactericidal antibodies.
These protein targets are summarized in Table 1. Display of Ng surface antigens on a vaccine
platform is possible using the virus-like particle and presents a novel solution for effective
Ng vaccine development.

10

Table 1: Summary of Ng Protein Targets

Protein
•

PorB

•
•
•
•

BamA
•

TbpA

•
•
•

MtrE

•
•

Function
Outer membrane porin
protein essential for
ion uptake
Cell invasion
Regulates apoptosis in
host cells
Mediates resistance to
complement-mediated
killing
Generates β-barrel
proteins on membrane
surface of gramnegative bacteria
Facilitates iron
scavenging from
human transferrin
Expressed in all Ng
isolates
Four exposed surface
loops make contact
with human transferrin
Component of
bacterial efflux pump
system
Outer membrane
channel
Antibiotic resistance

Conservation
Variable

Targeted Sequences
P1A1, P1A3, P1A5,
P1A7, P1A8, P1B5,
P1B7, P1B8

Highly
conserved

BamA L4, BamA L6,
BamA L7, BamA L8

Semiconserved

Plug Loop, L3, L7, L11

Highly
conserved

MtrE1, MtrE2

The Discovery of the Virus-Like Particle (VLP)
In 1968, an “Australia Antigen” was discovered in the sera of patients suffering from
Hepatitis (Bayer et al., 1968). The described particle was found to aggregate upon exposure
to antisera, suggesting that it was antigenic in nature and was associated with infectivity. This
unknown particle was a self-assembled collection of the antigenic Hepatitis B virus surface
antigen (Seeger & Mason, 2015) that was later termed a virus-like particle (VLP) because
these particles structurally resembled native virus, but were not infectious because they did
not encapsidate a viral genome. Subsequently, it was shown that many viral structural
proteins, when recombinantly overexpressed, could spontaneously self-assemble into VLPs.
VLPs from numerous viruses can be produced, including mammalian viruses, plant viruses,
11

and bacteriophage. VLPs have been employed in multiple applications, but this thesis will
focus on their use as vaccine platforms.
VLPs are characterized by their repetitive, multivalent structure and particulate nature,
both of which are important in interactions with immune cells that can lead to strong immune
responses (Chackerian, 2007). As VLPs are self-assemblies of multiple copies of structural
protein, they are naturally repetitive, multivalent structures. The size and particulate nature of
many VLPs not only allows them to be delivered specifically to peripheral lymphoid tissues
that are important for initiating adaptive immune responses, but also to antigen presenting
cells such as Dendritic cells, which enable antigen display and subsequent helper T-cell
activation (Fifis et al., 2004). Additionally, multivalent display of epitopes on the surface of
the VLP allows for simultaneous binding of multiple B-cell receptors on a single B-cell.
Simultaneous binding can promote B-cell receptor crosslinking and B-cell activation (Turner
et al., 2018). Enhanced B-cell activation is a driver for strong and sustained antibody
production.

Virus-Like Particles as Vaccines and Vaccine Platforms
Display of epitopes on VLPs promotes the adaptive immune response to and sustained
protection against pathogens. As mentioned, a critical feature of vaccines is their ability to
activate the adaptive immune system and promote the generation of protective antibody
responses. VLPs are beneficial for vaccine design, as their inherent structure promotes B-cell
activation. A prime example of the use of VLPs in vaccine development is the current human
papillomavirus (HPV) vaccine, Gardasil. In the early 1990s it was discovered that
overexpression of the HPV major capsid protein (L1) resulted in the production of HPV
VLPs. Gardasil contains VLPs derived from the 9 different HPV types that are most
commonly associated with cervical cancer and genital warts. In clinical trials, it was shown
that Gardasil induced strong antibody responses that dramatically reduced the incidence of
HPV infection in women (Koutsky et al., 2002). Importantly, even a single immunization
with the HPV vaccine elicited long-lived antibody responses in humans (Godi et al., 2019;
Villa et al., 2006), demonstrating the power of VLPs in promoting potent antibody responses.
HPV, like gonorrhea, is a sexually transmitted infection. The success of the VLP-based HPV
vaccine supports the use of VLP vaccines to defend against STIs.
12

VLPs may be used directly as vaccines and as vaccine platforms to display heterologous
targets. A wide variety of bacteriophage-derived VLPs can be chemically or genetically
modified to display peptide antigen in a repetitive fashion (Frietze et al., 2016). Advances in
molecular biology allow for diverse display of antigens on the surface of bacteriophage
VLPs. There are two prominent methods for antigen display: chemical conjugation and
genetic recombination (Figure 3).

A. Chemical conjugation of target molecules
Distribution of
surface lysines on the
surface of Qβ phage.

Target Peptide-GGC

SMPH

Qß bacteriophage

B. Genetic insertion of target peptides into the bacteriophage coat protein
AB-loop Insertion site

Target Peptide

coat

coat

MS2 Expression Plasmid
MS2 VLP with foreign
peptide on surface

MS2 VLP coat protein dimer

Figure 3: Methodologies for antigen display on the surface of Qβ (Panel A) and MS2 (Panel B) VLPs.
Chemical conjugation utilizes the SMPH bifunctional crosslinker to display linear peptides on the surface of
Qβ. Genetic insertion of antigens into the MS2 coat protein is performed using PCR to generate antigenic insert
sequences that are ligated into an expression plasmid encoding the MS2 coat protein dimer. These plasmids are
then expressed in an in-vitro E.coli system.

Conjugated VLPs: A variety of elements are expressed on the surface of VLPs that
enable chemical tethering of antigenic sequences. Common chemical conjugation techniques
rely on the expression of lysine or cysteine residues on the exterior of the VLP (Rohovie et
al., 2017). The Qβ bacteriophage VLP is made of 180 coat proteins in the fully assembled
virion, with each copy of the coat protein possessing multiple surface-displayed lysine
residues (shown in red in Figure 3A), all of which are potential chemical linkage sites (Cui et
al., 2017). Succinimidyl-6-(βS-maleimidopropionamido) hexanoate (SMPH) is a
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bifunctional, chemical crosslinker that can be employed to attach molecules to the surface of
VLPs. The amine-reactive arm of SMPH reacts with surface exposed lysine residues on the
Qβ virion, and the sulfhydryl-reactive are of the crosslinker can react with cysteine residues
that are incorporated onto either terminus of synthesized antigenic peptides (Morrow et al.,
2012). As such, antigenic peptides can be displayed in an unconstrained, linear fashion and in
high density on the surface of Qβ VLPs. Chemical conjugation is a relatively simple
technique which can be used to display peptides, full length proteins, or other molecules on
the surface of VLPs, and this approach typically results in display of numerous (>100) copies
of the target antigen on the surface of the VLP. A potential downside to this method is that
peptides may not be displayed in their native conformations. For example, if a peptide
naturally exists within a surface exposed loop, the immune response generated against an
unrestrained form of the peptide, as displayed on the surface of Qβ, might not be the same as
the response generated against the native form.
Recombinant VLPs: In order to display antigens in a more native conformation, genetic
recombination can be used to incorporate target antigens into the physical coat protein
sequence. The wild-type MS2 VLP coat protein exists as a single copy containing an AB
loop that protrudes from the base structure. Unfortunately, the coat protein is not tolerant of
heterologous peptide insertions, but a version of the MS2 coat protein that consists of a single
chain dimer is more amenable to peptide insertions (Peabody et al., 2008). Peptides can be
inserted at two different surface-exposed sites on the MS2 single-chain dimer, the Nterminus and the AB loop of the second copy of the MS2 coat protein. Using either insertion
site, exactly 90 copies of the target antigen are be displayed per MS2 VLP. In the studies
described in this thesis, we focused on AB loop display of Ng peptides. The Ng peptides that
we targeted are derived from extracellular loops and we hypothesized that display within the
AB loop would better mimic their native conformation. However, a significant disadvantage
of this method is that certain lengthy inserts might disrupt VLP assembly, in which case
shorter versions of target antigens may need to be substituted.
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Preliminary Data
Preliminary data supports the use of a VLP platform in the development of an Ng
vaccine. Dr. Naomi Lee, a previous lab member, constructed 7 VLPs displaying PorB and
MtrE Ng targets in both conjugated and recombinant fashions. Dr. Ann Jerse of Uniformed
Services University of the Health Sciences immunized mice 3 times, initially subcutaneously,
followed by 2 intranasal immunizations. Anti-peptide IgG and IgA titers were measured from
sera and vaginal washes (Figure 4).
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Figure 4: Antibody responses from mice immunized with 4 VLP candidates displaying Ng epitopes (PorB,
MtrE). Antibody responses were measured via end-point dilution peptide ELISA. Serum was collected at day
70 (black circles) and vaginal washes were collected at day 42 (red circles). Data provided by Dr. Ann Jerse.

Detectable IgG and IgA responses were measured in both sample types in all four of
the vaccinated groups shown, indicated that VLP based vaccines promoted isotype-switched
antibody responses against Ng antigens. Serum bactericidal activity (SBA) assays were also
performed on sera collected from mice immunized with two conjugated VLPs displaying
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MtrE epitopes (Figure 5). Sera was combined with a source of human complement and then
applied to two Ng strains: FA19 and DW3FA19 (which does not express the MtrE protein).
FA19 – Qß-Mtr1

FA19 – Qß-Mtr2

Heat-inactivated serum

CFU
Active serum

Serum dilution (1:x)

DW3FA19 – Qß-Mtr1

DW3FA19 – Qß-Mtr2

CFU

Serum dilution (1:x)

Figure 5: Serum bactericidal activity measured in sera collected from mice immunized with two conjugated
VLP candidates displaying MtrE epitopes. Human serum was used a source of complement. Heat-inactivated
serum refers to heat-inactivated human complement (negative control), while active serum refers to active
human complement. Sera from immunized mice was bactericidal against strain FA19 (A & C) but not against
strain DW3FA19 (B & D), which does not express MtrE. Data provided by Dr. Ann Jerse

Bactericidal activity was noted against FA19 but not against DW3FA19, demonstrating
that MtrE conjugated VLP vaccines elicited antibody responses directed against MtrE
antigens that could kill Ng. Together, these data, along with the success of Gardasil (a VLPbased vaccine for another STI), encourage the use of VLPs to display Ng antigens in
designing vaccine candidates.

Hypothesis, Relevance, Innovation, and Aims:
Virus-like particles (VLPs) are amenable for the display of a variety of N.
gonorrhoeae epitopes for the generation of a prophylactic vaccine to prevent gonorrhea. This
study is relevant, as there is no current vaccine for gonorrhea. Increasing resistance to
antibiotic treatment and complications associated with asymptomatic infection are pressing
public health issues, and a vaccine is essential for limiting infection and transmission. The
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virus-like particle is innovative in its ability to display target antigens in a multivalent
manner, as well as its inherent adjuvant properties and small size that facilitate direct
activation of the immune system. The specific aims of this study are to:
1. Engineer recombinant and conjugated N. gonorrhoeae VLPs using two
independent VLP platforms – the MS2 bacteriophage VLP and the Qβ
bacteriophage VLP.
2. Immunize mice with candidate vaccines and measure systemic antibody
responses via peptide ELISA.
3. Measure antibody binding to recombinant protein and whole pathogen.
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CHAPTER 2
METHODOLOGY
Generating Recombinant VLP Vaccine Candidates: The pDSP62 plasmid encodes for the
single chain dimer of the MS2 bacteriophage coat protein sequence (Peabody et al., 2008)
(Figure 5). Heterologous sequences were genetically inserted into the AB loop of the
downstream copy of the coat protein sequence by polymerase chain reaction (PCR). PCR
primers were designed to encode the peptide sequences shown in Appendix A. If peptide
sequences were longer than 10 amino acids, the middle 10 amino acids of the antigenic
sequence were used in primer design. Designed forward primers anneal just upstream of the
AB loop of the second MS2 coat protein sequence in pDSP62, and the E3.2 reverse primer
(5’ CGGGCTTTGTTAGCAGCCGG 3’) anneals downstream of the second coat protein
sequence. A list of designed forward PCR primers can be found in Appendix B. PCR
products were digested using SalI and BamHI (high fidelity, NEB), whose restriction sites
flank the MS2 AB loop of the second copy of coat protein, respectively (Chackerian et al.,
2011). Digested PCR products were cloned into the pDSP62 vector after digestion with SalI
and BamHI. Following ligation and plasmid purification, plasmids were cloned into 10G E.
coli to obtain a plasmid prep. Clones were validated by sequence analysis. Recombinant
VLPs were expressed by transforming electrocompetent C41 E. coli with plasmid. Colonies
were grown in LB media to an (OD)600 of 0.6 and treated with 0.5 mM Isopropyl β-d-1thiogalactopyranoside (IPTG) for 3 hours. Following induction, cells were pelleted and
stored at -80°C. The following day, pellets were freeze-thawed three times. Cells were then
resuspended in a solution containing 50mM tris-HCl (pH 8.5), 100mM NaCl, 10mM EDTA,
10mM DTT, and 0.2 mg/mL hen egg lysozyme. Reactions were incubated for 1 hour at room
temperature. After incubation with lysozyme solution, 10% deoxycholic acid (DOC) solution
was added to the reaction, at a final concentration of 0.05% DOC, and the reaction incubated
for 30 minutes at room temperature. Reactions were sonicated 5 times in 30 second intervals
to further lyse bacterial cells. To eliminate any contaminating DNA, reactions were then
treated with 10 µg/mL DNase and 100 mM MgCl and incubated at room temperature for 1
hour. Reactions were spun at 3750 rpm for 30 minutes to collect debris. To mediate
precipitation of the VLPs, the supernatant was treated with ammonium sulfate at a final
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saturation of 60% and incubated on ice for 10 minutes. The reaction was spun again at
10,000 rpm for 10 minutes. The spun pellet was resuspended in 1 mL of sepharose column
buffer (SCB) (1% tris-HCl pH 7.4, 2% 5M NaCl, 0.1% 1M MgSO4 in H2O) and frozen
overnight. VLPs were purified by size exclusion chromatography using Sepharose 4B (Sigma
Aldrich). Frozen reactions were thawed and spun again at 10,000 rpm for 10 minutes before
supernatant was applied to the sepharose column. Column fractions were first run on an
agarose gel to confirm the presence of RNA encased inside the MS2 VLPs. Fractions
containing purified VLPs were then pooled together and VLPs were further precipitated with
a 70% ammonium sulfate saturation. After centrifugation at 10,000 rpm for 10 minutes,
pellets were suspended in 1 mL of PBS and dialyzed against PBS overnight at 4°C. VLP
concentrations were estimated by running purified product on an SDS-PAGE gel and
comparing to a hen-egg lysozyme standard (Figure 6).

1 2 3 4 5
6 7 8 9 10

Figure 6: Generating recombinant VLPs. Left: The plasmid vector pDSP62 encoding the MS2 coat
protein dimer (Chackerian et al., 2011); Right: SDS-PAGE gel electrophoresis of purified recombinant
VLPs displaying Ng targets. 1: MS2-P1A7 (1 µL); 2: MS2-BamA L6 (1 µL); 3: MS2-BamA L6 (2 µL);
4: MS2-BamA L7 (1 µL); 5: MS2-BamA L7 (2 µL); 6-10: Hen-egg lysozyme standards 0.25 µg/µL,
0.5 µg/µL, 1 µg/µL, 2 µg/µL, 3 µg/µL, respectively.

Generating Conjugated VLP Vaccine Candidates: To generate conjugate VLP candidates,
antigenic peptide sequences (Appendix A) were synthesized. Each peptide was designed to
contain the residues glycine-glycine-glycine-cysteine at the C-terminus to facilitate
conjugation to VLPs. Qβ bacteriophage VLPs were generated with the pETQCT plasmid
following the protocol described above. To attach peptides to the surface of Qβ, VLPs were
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reacted with a bifunctional crosslinker (SMPH) at a 1:4 molar ratio. After removing excess
SMPH using an Amicon Ultra-4 centrifugal filter, peptide was added to the Qβ VLPs at a
10:1 molar ratio. Conjugation efficiency was measured using an SDS-PAGE gel (an example
is shown in Figure 7). Coat protein that has been conjugated to peptide has a higher
molecular weight than unconjugated Qβ, so the efficiency of conjugation was determined by
calculating the percentage of Qβ coat protein with one or more peptides attached.
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Figure 7: Generating conjugated VLPs. SDS-PAGE gel electrophoresis of purified conjugated VLPs displaying
Ng targets. 1-4: Hen-egg lysozyme standards 0.25 µg/µL, 0.5 µg/µL, 1 µg/µL, 2 µg/µL, respectively; 5: Qβ
unconjugated control (2.5 µg/µL); 6: Qβ-BamA L4 C-terminus in PBS (5 µL); 7: Qβ-BamA L4 C-terminus in
DMSO (5 µL); 8: Qβ-BamA L6 (5µL); 9: Qβ-BamA L7 (5 µL). The red arrow points to successful conjugation
of one BamA L4 peptide to one copy of Qβ coat protein. The yellow arrow points to successful conjugation of
two BamA L4 peptides to one copy of Qβ coat protein.

Mouse Immunizations and Sera Collection: Female Balb/c mice were immunized
intramuscularly with 5 µg of candidate VLPs or control VLPs (N = 5 mice per candidate
VLP; MS2 or Qβ VLPs used as controls) at three-week intervals. Two weeks following the
second immunization, retroorbital bleeds were performed. Two weeks following the third
immunization, terminal blood was collected via cardiac puncture.

Measuring Antibody Responses via Peptide ELISA: To measure the ability of elicited
antibodies to bind to target antigens, peptide ELISAs were performed, as previously
described (Crossey et al., 2015). Peptides were tethered to the well surface of ELISA plates
using streptavidin and SMPH. ELISA plates (Immunlon 2 HB, ThermoFisher) were coated
with 500 ng of streptavidin per well for 2 hours at 37° C, followed by 250 ng of SMPH per
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well for 2 hours at room temperature. Plates were washed 5 times with PBS. Synthesized
peptides containing a C-terminal cysteine were added to the ELISA plates at a concentration
of 1 µg per well and incubated overnight at 4°C. Plates were washed 5 times again with PBS,
and wells were blocked with 0.5% milk in phosphate buffered saline (PBS) for 2 hours. After
washing 5 times with PBS, four-fold dilutions of mouse sera (starting at a 1:40 dilution) were
added to wells and incubated for 2 hours at room temperature. Plates were washed 5 times
with PBS. ELISA plates were probed with horseradish peroxidase (HRP)-conjugated
secondary antibody [goat anti-mouse-IgG (Jackson ImmunoResearch; 1:5,000)] for one hour,
washed 5 times with PBS, and developed using 3,3’,5,5’-Tetramethylbenzidine (TMB,
ThermoScientific). A 1% hydrochloric acid solution was used to stop the reaction. Optical
density at 450 nm (OD450) was used to measure reactivity of sera to the target antigen.

Ng Strains: Sequences of the four protein targets from laboratory Ng strains FA1090, FA19,
MS11, F62, H041 were kindly provided by Robert Nicholas from the University of North
Carolina. The sequences were used to determine which strains of Ng were appropriate for
imaging flow cytometry and serum bactericidal activity assays. Protein sequences were
aligned using SnapGene® software (from GSL Biotech; available at snapgene.com). Strains
used for antibody binding assays were chosen by identifying antigenic sequences used to
design VLPs within each strain’s respective protein sequence. Two Ng strains were used for
imaging flow cytometry and serum bactericidal activity assays: FA1090 and FA19. Both
strains are common experimental Ng strains. FA1090 was isolated from a patient with
disseminated gonococcal infection in the 1970s and expresses porin serotype P1B-3 (Hobbs
et al., 2011). FA19 was also isolated from a patient with disseminated infection in 1962 and
expresses the P1A por allele (Abrams et al., 2015).

Imaging Flow Cytometry: Imaging flow cytometry assays were conducted by collaborators
Dr. Alison Criss and Mrs. Mary Gray of the University of Virginia. This assay was
performed to measure the ability of antibodies produced in response to immunization with
candidate VLPs to bind to whole pathogen (Ng strains FA1090 and FA19). From a stock of 2
x 108 cells/mL in RPMI, 25 µL of bacteria was mixed with mouse sera diluted 1:10 in RMPI
in a V-bottom 96-well plate and incubated for 30 minutes at 37°C in a 5% CO2 environment.
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As positive controls, bacteria were incubated with anti-porin antibody (H5.2, IgG; Gift from
Dr. Marcia Hobbs at the University of North Carolina) or with anti-LOS antibody (6B4, IgM;
Gift from Dr. Sanjay Ram at the University of Massachusetts). Following incubation, 200
µL of a 10% heat-inactivated fetal bovine serum (FBS) in RPMI 1640 (HyClone, 1X)
solution was added to each well. Plates were spun at 3990 rpm for 7 minutes at room
temperature. The FBS mix was then removed, and the FBS washing step was repeated for a
total of three times. Plates were then incubated with 50 µL of 1:100 diluted AF488 goat antimouse IgG antibody (Jackson ImmunoResearch) or with AF647 goat anti-mouse IgM
antibody (Jackson ImmunoResearch) for 30 minutes at 37°C in a 5% CO2 environment.
Plates were washed with PBS, then spun again at 3990 rpm for 7 minutes at room
temperature. After removal of 200 µL of liquid, the remaining liquid was used to resuspend
the spun pellet, of which 70 µL was transferred to a round-bottom 96-well plate. To the
removed volume, 15 µL of 1:100 diluted 4′,6-diamidino-2-phenylindole (DAPI) in 16%
paraformaldehyde (PFA) was added and samples were analyzed on the Image Stream Flow
Cytometer.

Measuring Serum Bactericidal Activity (SBA): Serum bactericidal assays were also
conducted by collaborators Dr. Alison Criss and Mrs. Mary Gray of the University of
Virginia. This assay was performed in order to assess the ability of antibodies elicited by
VLP vaccination to kill live Ng (Johnson & Criss, 2013; Kellogg et al., 1963). Briefly, sera
samples were diluted 1:50 (if tested against FA1090) or 1:100 (if tested against FA19) in
RPMI 1640 media and added to a round-bottom 96-well plate containing approximately 1000
Ng cells per well. Plates were incubated at 37°C for 15 minutes in a 5% CO2 environment.
Sera samples were tested in duplicate, where sample was incubated with 2X concentrations
of either active or heat-inactive human sera depleted of IgM and IgG (Igd-NHS; PelFreez).
Plates were then incubated at 37°C for 45 minutes in a 5% CO2 environment. After
incubation, 100 µL of gonococcal growth liquid medium (GCBL) was added to each well.
Reactions were mixed, and 20 µL of reaction were plates on gonococcal growth agar (GCB)
to grow overnight at 37°C in a 5% CO2 environment. Individual colonies on agar plates
represented one colony forming unit (CFU) and were tabulated on both experimental and
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negative control plates. In order to calculate bactericidal activity, the following equation was
used:

𝐾𝑖𝑙𝑙𝑖𝑛𝑔 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =

# 𝐶𝐹𝑈𝑠 𝑝𝑒𝑟 20 µ𝐿 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑎𝑐𝑡𝑖𝑣𝑒 𝐼𝑔𝑑 − 𝑁𝐻𝑆
∗ 100
#𝐶𝐹𝑈𝑠 𝑝𝑒𝑟 20 µ𝐿 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒 𝐼𝑔𝑑 − 𝑁𝐻𝑆

If sera samples had less than 50% killing activity, bactericidal activity was reported as
negative for the particular sera dilution. If sera samples had 50% killing activity or greater,
sera samples were serially diluted 1:2 for a total of 5 dilutions and retested. The dilution at
which 50% killing was observed was reported. 6B4 antibodies (diluted 1:400) were used as
positive controls and RPMI media only as a negative control.
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CHAPTER 3
RESULTS
Conjugated and recombinant VLPs displaying multiple epitopes from PorB, BamA,
TbpA, and MtrE were generated. In total, 37 Ng VLP candidates were constructed: 18 MS2
recombinant VLPs and 19 Qβ conjugated VLPs (Appendix A).
Some of the proteins chosen as vaccine targets are semi-conserved among Ng strains
(Table 1). Sequences of the four protein targets (PorB, BamA, TbpA, MtrE) from five
common laboratory strains of Ng (FA1090, FA19, MS11, F62, H041) were aligned to
identify the locations of loop sequences within each respective protein, as well as to
determine the relative conservation of each targeted loop’s sequence (Figure 8a-d)
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Figure 8a: Aligned sequences of Ng PorB from five Ng strains: FA1090, FA19, MS11, F62, and
H061, respectively. PorB loop sequences are given in the tables and are highlighted with red boxes.
Colored bars above the sequences illustrate the relative conservation of each amino acid among the
five strains.
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Figure 9a: Aligned sequences of Ng BamA from five Ng strains: FA1090, FA19, MS11,
F62, and H061, respectively. BamA loop sequences are given in the tables and are
highlighted with red boxes. Colored bars above the sequences illustrate the relative
conservation of each amino acid among the five strains.

26

Figure 8c: Aligned sequences of Ng TbpA from five Ng strains: FA1090, FA19, MS11, F62, and
H061, respectively. TbpA loop sequences are given in the tables and are highlighted with red boxes.
Colored bars above the sequences illustrate the relative conservation of each amino acid among the
five strains.
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Figure 8d: Aligned sequences of Ng MtrE from five Ng strains: FA1090, FA19, MS11, F62, and
H061, respectively. MtrE loop sequences are given in the tables and are highlighted with red boxes.
Colored bars above the sequences illustrate the relative conservation of each amino acid among the
five strains.
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As expected, extracellular loop sequences in BamA and MtrE were highly conserved
among all strains of Ng. PorB had the greatest heterogeneity in expression between Ng
strains, followed by TbpA.
Mice were immunized with candidate VLPs, and sera was collected following second
and third immunizations. Peptide ELISAs were performed against collected sera.

Figure 9: Peptide ELISA data measuring antibody responses in terminal sera (collected two weeks following
third immunization from mice immunized with conjugate VLPs). X-axis represents sera dilution up to
1:655360. Y-axis represents optical density at 450 nm.

Figure 9 shows ELISA data from mice immunized with peptides conjugated to Qß
VLPs. In general, immunized mice produced high-titer antibodies that were able to bind to
peptide displayed on the surface of the ELISA plate. There was some variability in IgG
responses from mouse to mouse and from peptide to peptide. Mice immunized with control
VLPs (Qβ) did not generate antibodies that were able to bind any of the antigenic peptides
displayed on the experimental VLPs, as anticipated.
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Figure 10: Peptide ELISA data measuring antibody responses in terminal sera (collected two weeks following
third immunization from mice immunized with recombinant VLPs). X-axis represents sera dilution up to
1:655360. Y-axis represents optical density at 450 nm.

Figure 10 shows ELISA data from mice immunized with peptides displayed on
recombinant MS2 VLPs. Although mice in almost all vaccinated groups were able to
generate antibodies that could bind to linear peptide as displayed on the surface of the ELISA
plate, some responses were lower in comparison to mice immunized with their conjugated
VLP counterpart. Additionally, there was greater variability in responses between individual
mice in the same experimental group. Mice immunized with control VLPs (MS2) did not
produce antibodies that could bind any of the antigenic sequences displayed recombinantly in
any of the experimental VLPs, again, as anticipated.
Antibody binding to native protein and whole pathogen is essential in vaccine
development. To determine whether elicited antibodies were capable of binding whole
pathogen, collaborators at the University of Virginia performed imaging flow cytometry
assays (Figure 11a-b) using sera from mice immunized with a subset of the VLPs.
Differential expression of protein targets among strains may complicate assays that assess
antibody binding. For example, antibodies produced in response to VLPs displaying Por
antigens derived from the P1A allele may not react to an Ng strain expressing a porin protein
encoded by the P1B allele. Additionally, efficacy of vaccine candidates may be limited if
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certain targets are not ubiquitously expressed among common strains of Ng. Therefore, it was
critical to determine the appropriate experimental strains for testing. Using aligned protein
sequences to assess conservation of target sequences (Figure 8a-d) , we decided to use strain
FA1090 to measure whether antibodies elicited by VLPs expressing BamA, MtrE, and PorB
P1B antigens could bind whole pathogen. Strain FA19 was used to asses binding of
antibodies elicited by VLPs expressing PorB P1A and TbpA antigens.
The sample subset tested using imaging flow cytometry included sera from mice
immunized with the following VLPs: P1A5 (conjugated and recombinant), BamA L4 – Cterminus (conjugated and recombinant), TbpA L7 (conjugated and recombinant), and MtrE1
(conjugated and recombinant).
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Figure 11a: Image Stream data collected at the University of Virginia measuring IgM binding to Ng. The mean
fluorescence intensity is given in the top panel of the graph, and the percentage of Ig-bound bacteria is given in
the bottom panel of the graph. X-axis sample numbers correspond with individual mice within each
immunization group (Appendix B). 6B4/Porin serve as positive controls. Negative controls represented by black
bars (sample numbers 23-27 and 64-67) are sera from mice immunized with Qβ or MS2 alone, respectively).
Isotype control antibodies were also used as negative controls.
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Figure 11b: Image Stream data collected at the University of Virginia measuring IgG binding to Ng. The mean
fluorescence intensity is given in the top panel of the graph, and the percentage of Ig-bound bacteria is given in
the bottom panel of the graph. X-axis sample numbers correspond with individual mice within each
immunization group (Appendix B). 6B4/Porin serve as positive controls. Negative controls represented by black
bars (sample numbers 23-27 and 64-67) are sera from mice immunized with Qβ or MS2 alone, respectively).
Isotype control antibodies were also used as negative controls.
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In general, sera from most mice immunized with candidate Ng VLPs contained IgM
and/or IgG antibodies which bound to Ng. However, some negative control mice (immunized
with Qβ or MS2 only) also produced IgM antibody responses that reacted with whole
pathogen, suggesting that IgG binding may be a better tool for assessing whether vaccination
produced Ng-binding antibodies. These data show that a subset of vaccinated mice produce
IgG that is capable of binding to Ng. For example, four out of five mice immunized with
P1A5 conjugated to Qß have IgG that bind to Ng higher than background levels.
Antibody binding can promote activation of complement and bacterial killing
through the membrane attack complex (MAC). To measure the ability of antibodies elicited
by candidate vaccines to promote complement-mediated killing, serum bactericidal activity
(SBA) assays were performed by collaborators at the University of Virginia. Bactericidal
activity of sera collected from mice immunized with BamA, MtrE, and PorB P1B antigens
was measured against strain FA1090, while sera from mice immunized with PorB P1A and
TbpA antigens was tested against strain FA19 (Figure 12).
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Figure 12: Serum bactericidal activity assays performed at the University of Virginia to measure the ability of
elicited antibodies to kill live Ng. Bactericidal activity is reported as 0% viable bacteria in comparison to
bacteria treated with heat-inactivated complement (y-axis). X-axis sample numbers correspond with individual
mice within each immunization group (Appendix B). RPMI represent negative controls – bacteria treated with
media only. 6B4/Porin serve as positive controls.
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Most sera samples tested demonstrated some level of bactericidal activity. For
example, sera from sample #s 13-17 (mice immunized with P1A5 conjugated VLPs) was
able to promote killing of Ng when combined with human complement. However,
bactericidal activity was also noted in about half of the negative control mouse sera (sample
#s 64, 124, and 126), suggesting that Ng-reactive IgM can activate complement. Negative
control serum was collected from mice immunized with MS2 or Qβ alone, therefore negative
control sera should be unreactive against whole pathogen.
The concern about bactericidal activity observed in some negative control sera
samples was further evaluated (Figure 13a-b). ImageStream data was compared to SBA for
four negative control samples (#s 64, 65, 124, and 125) to determine whether sera contained
IgM or IgG that were reactive to pathogen and therefore may be promoting complementmediated killing. Sera was analyzed against both FA1090 and FA19 strains of Ng, as sera
should ideally be unreactive to both.

Figure 13a: Evaluation of bactericidal activity observed in negative control sera against strain FA1090. Flow
cytometry data is represented on the left-hand side of the image, and bactericidal activity is represented on the
right-hand side of the image. Graphs on the right-hand side of the image represent bactericidal activity of sera
after serial dilutions. Graph legends provide the sera dilution at which 50% bactericidal activity was observed.
6B4/Porin antibody was used as a positive control for flow cytometry and SBA assays, and RPMI was used as a
negative control for SBA assays.
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Figure 13b: Evaluation of bactericidal activity observed in negative control sera against strain FA19. Flow
cytometry data is represented on the left-hand side of the image, and bactericidal activity is represented on the
right-hand side of the image. Graphs on the right-hand side of the image represent bactericidal activity of sera
after serial dilutions. Graph legends provide the sera dilution at which 50% bactericidal activity was observed.
6B4/Porin antibody was used as a positive control for flow cytometry and SBA assays, and RPMI was used as
a negative control for SBA assays.

Immunization with control VLPs (Qβ and MS2) did not induce IgM or IgG antibodies
with strong binding to either FA1090 or FA19. The only exception was mouse 124, whose
sera contained IgM capable of binding strain FA19 at levels greater than the positive control.
Serum bactericidal activity against strains FA1090 and FA19 was reported in sample 64, and
bactericidal activity was also seen against strain FA19 in sample 124. These data suggest the
presence of cross-reactive antibodies in mouse sera that can bind and promote killing of
whole pathogen.
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CHAPTER 4
DISCUSSION
Using two complementary VLP platforms, a total of 37 VLPs displaying a variety of
Ng antigenic sequences from four different Ng proteins were engineered. Mice were
immunized with these VLPs, and a number of preliminary studies were performed to assess
immune responses. These assays included peptide ELISA, imaging flow cytometry, and
serum bactericidal activity assays.
Immunization with candidate VLPs elicited high-titer antibodies that were able to
bind linear Ng peptides, as measured by peptide ELISA (Figures 9 & 10). There was some
variability between mouse responses within each immunization group, and this was more
apparent in groups immunized with recombinant VLPs. Additionally, some mice immunized
with recombinant VLPs (MtrE1, MtrE2) did not elicit strong antibody responses to respective
Ng peptides (Figure 10). It is possible that antibody responses generated after immunization
with recombinant VLP candidates may not appear to be as reactive to antigen (in comparison
to their conjugate VLP counterparts) when measured by peptide ELISA simply due to the
nature of the assay. Peptide antigens are displayed in a linear fashion by means of chemical
conjugation to the ELISA plate using SMPH, the same method used to conjugate antigen to
Qβ VLPs. This may explain why antibodies elicited after conjugated VLP vaccination in
almost all experimental groups bind to linear peptide better than antibodies produced after
immunization with recombinant VLPs. Additionally, Qβ VLPs typically display 180 or more
copies of antigenic peptide, while the MS2 VLP is restricted to displaying exactly 90 copies
of antigenic sequence. Multivalent display of antigens is critical for B-cell receptor
activation, so it is possible that conjugated VLPs elicit higher titer antibody responses
because target peptides are displayed at higher valency. Nevertheless, peptide ELISA alone is
insufficient in determining which VLP candidates have the most potential as a vaccine
because it is not necessarily predictive of binding to native antigen. Display of Ng epitopes in
a constrained loop, as is the case with the recombinant VLPs, might elicit better antibody
responses against recombinant protein or native antigen rather than linear peptide.
The goal of our vaccine approach is to elicit antibodies that react against the antigen
target in its native conformation in Ng. Collaborators at the University of Virginia conducted
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imaging flow cytometry assays on a subset of mouse sera to measure the degree of IgM and
IgG binding to whole pathogen (Figure 11a-b). Overall, mice immunized with candidate
VLPs had IgM and IgG responses that reacted to whole pathogen. Responses were quite
variable, however, with some mice having produced more reactive antibody than others.
Additionally, it appeared as though the percentage of IgM-bound Ng was greater than the
percentage of IgG-bound Ng across all samples tested. Sera used in testing was collected 56
days following initial immunization, which is sufficient time for B-cell class switching and
increased production of IgG (Abbas et al., 2018a), thus it is unlikely that Ng-binding IgM
was elicited by vaccination. It is possible that mice produce IgM antibody, perhaps in
response to their natural flora or an infection, that cross-reacted with Ng. For example, pili
and lipooligosaccharides (LOS) are expressed by numerous bacterial species, are highly
antigenic, and can trigger broadly reactive immune responses.
Not only were IgM responses higher in experimental groups, but also in a subset of
control mice (Figure 11a-b). Again, these control mice may have generated a non-specific
antibody response against various exogenous antigens that was also reactive with Ng. This
phenomenon was observed in serum bactericidal assays (Figure 12). Bactericidal activity is
important in selecting vaccine candidates, as it is reflective of the ability of elicited
antibodies to not only bind target antigen but also to stimulate downstream effector functions
via the complement system. Although most tested experimental sera samples were
bactericidal, a subset of control sera also had bactericidal activity, prompting further
investigation (Figure 13a-b). Three out of five control samples showed bactericidal activity.
Interestingly, there was minimal IgG binding to either FA19 or FA1090 in control samples
tested, but a trend towards higher IgM responses against FA19. This may indicate that it is
indeed a non-specific IgM response generated by control mice that contributed to the
bactericidal activity seen in their sera. Of course, these data may imply that experimental
mice might be generating similar non-specific antibody responses that can kill Ng when
combined with human complement.
IgG responses, although not as strong as IgM responses, were still measured in sera of
experimental mice. Mice immunized with P1A5 conjugated VLPs produced IgG responses
higher than the background measured in control sera. Imaging flow cytometry, therefore,
may still be a good measure of Ng-specific IgG produced after vaccination.
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Unfortunately, imaging flow cytometry cannot identify antibody responses that are
specific to the antigenic target, as any bound IgM or IgG can be detected. SBA assays cannot
distinguish complement-mediated killing by Ig subtype, as both IgM and IgG can fix
complement (Borsos, 1971). In other words, it is difficult to determine whether bactericidal
activity is attributable to cross-reactive IgM, or vaccine induced IgG. Further, IgM is better at
promoting complement-mediated killing than IgG, further confounding the results (Charles A
Janeway et al., 2001). A limitation of both assays is that they do not account for variability in
expression of Ng target proteins. Certain targeted epitopes might be occluded in their native
format, and therefore more difficult for antibodies to access. Additionally, certain proteins
are not ubiquitously expressed, such as TbpA, which is usually only expressed at high levels
if Ng is iron-starved (Ronpirin et al., 2001). This complicates the in-vitro imaging flow
cytometry and SBA assays, as it does not consider the accessibility of each target antigen.
There are a variety of solutions to eliminate confounding effects of cross-reactive
immune responses. One way to measure whether SBA is based on antigen-specific antibody
responses is to use mutant Ng strains that lack target antigens (Figure 5). If SBA persists
when mutant strains lacking target antigens are treated with sera from mice immunized with
those target antigens, it can be concluded that non-specific Ig activity is contributing to SBA.
One drawback of this solution is that some of the target proteins are required for Ng survival,
so mutation may not be tolerated. Another solution that clarifies whether antibody binding
and SBA is attributable to generic antibodies or to antibodies produced in response to
vaccination is to absorb collected sera against E. coli lysate. In this assay, pelleted E. coli is
incubated with collected sera to eliminate any antibodies that can bind generic bacterial
targets. This process will ideally exclude generic antibody responses that are not indicative of
vaccine efficacy but are rather an artifact of bacterial exposure or infection in immunized
mice.
There are three VLP candidates that are promising, as evidenced by peptide ELISAs,
imaging flow cytometry, and SBA assays: P1A5 conjugated, TbpA L7 conjugated, and
MtrE1 conjugated VLPs (Table 2). Generally, these VLPs induced strong antibody responses
that were able to bind to both linear peptide and whole pathogen and promote killing of live
Ng. All three are conjugated VLPs, where peptide antigen is displayed in an unconstrained or
linear fashion. The strong antibody response observed with peptide ELISAs may be an
40

artifact of the assay itself. Additionally, the greater valency of Qβ might encourage higher
titer antibody responses. P1A5 conjugated VLPs stimulated the production of IgM and some
IgG that could bind whole pathogen. Additionally, SBA was observed in all sera samples
collected from mice immunized with P1A5 conjugated VLPs. PorB is abundantly expressed
in the Ng outer membrane, so greater accessibility to target antigen might contribute to
greater Ig binding and killing. It will be interesting to compare P1A5 conjugated VLPs to
other VLP candidates expressing PorB antigens.
Table 2: Summary of VLP-based vaccine candidates assessed via peptide ELISA, imaging flow cytometry, and
SBA assays

VLP Candidate

Peptide
ELISA

Imaging Flow
Cytometry
IgM

IgG

SBA

P1A5 - C

+++

++

+

+++

TbpA L7 - C

+++

+

+

++

MtrE1- C

+++

+

+

+

BamA L4 Cterminus – R
TbpA L7 - R

++

-

-

+

+++

-

-

++

Future Directions:
To address the ability of elicited IgG antibodies to bind target antigen, recombinant
protein ELISAs will be conducted by collaborator Andrew Macintyre at Duke University. In
this indirect ELISA assay, recombinant proteins will be tethered to ELISA plates to analyze
antibody reactivity in the sera of immunized mice. This assay verifies that elicited antibodies
can bind to whole protein and will serve as an additional tool to allow us to assess our
vaccine candidates.
In addition, VLP-based Ng vaccine candidates will be screened for their ability to
elicit high-titer antibodies that bind target antigen and promote bacterial clearance via two
other antibody effector functions: opsonophagocytosis and inhibition of target function via
steric hinderance.
Collaborator Dr. Alison Criss at the University of Virginia will conduct
opsonophagocytic activity (OPA) assays to measure the opsonization effector function of the
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antibody responses. Briefly, Ng will be treated with sera from immunized mice and a source
of human complement depleted of IgM and complement factor 6, and then incubated with
human promyelocytic cells. Antibody binding will ideally enhance phagocytosis by the
promyelocytic cells. Cell killing via opsonophagocytosis will be assessed by plating bacteria
and quantifying the reduction in colonies.
A variety of assays can be performed to measure whether elicited antibodies can
physically limit the functionally of target antigens. For example, we plan on growing live Ng
and using a whole-cell ligand-blocking ELISA to measure whether antibodies generated
against TbpA targets can limit the sequestration of iron by Ng. In this assay, live, iron-starved
Ng cells are plated onto ELISA plates. Sera from immunized mice will be applied following
a blocking step, HRP-labelled human transferrin protein will be added to the plate, and TMB
will be used to detect bound transferrin. Gonococcal TbpA binds human transferrin to
sequester iron, so if immunized mouse sera can effectively bind to TbpA and block its
function, then plated Ng should not be able to bind to human transferrin.
Assessing which vaccine candidates show the greatest potential in inducing protective
immune responses requires a tiered approach. Antibodies produced in response to
vaccination should meet the basic requirement of binding to native protein and pathogen.
This property can be assessed with peptide ELISAs, recombinant protein ELISAs, and
imaging flow cytometry. Once the basic requirement of binding is met, further assays
including SBA, OPA, and inhibition of target function will be conducted to further screen
vaccine candidates. Based on data collected thus far, certain VLP candidates are promising
(Table 2). Nevertheless, assay optimization and elimination of confounding variables is
necessary to evaluate vaccine candidates thoroughly.

Conclusion:
Preliminary immunological studies have shown that immunization with VLP-based
vaccines expressing a variety of N. gonorrhoeae antigenic epitopes promotes the production
of high-titer antibodies that can bind linear antigen and, in some cases, whole pathogen.
Further studies are necessary to screen candidate VLPs for their ability to promote antibody
responses that can neutralize pathogen via downstream effector functions. Overall, the data
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presented in this study support the use of VLP-based platform in designing an effective
vaccine against gonococcal infection.
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APPENDIX A
Table of Antigenic Sequences Used to Generate VLP Candidates
Antigen/Loop
PorB
P1A1
P1A3

Sequence for Conjugation

Sequence(s) for
Recombination
AHHGAQADRVKT
GRLNSVLKDT
&
PWEGKSYYLG

P1A5

AHHGAQADRVKT
GRLNSVLKDTGGFNPWE
GKSYYLGLSNIAQPEERH
VSV
RYGEGTKKLEYFHQVYS
LPSLFVEK
RHSYTTEKH

P1A7

FKGSVYDADNDNTYD

P1B5

RHSYTTEKH

Rationale

VLPs
Constructed

Interacts with C4BP
Mediates cellular
invasion through
SREC
Interacts with C4BP

C&R
C&R

Highly conserved
amongst P1A strains
P1A analogue of
P1B7
Conserved C-term of
loop 7
Loop 8 is largely
conserved
P1A analogue of
P1B8

C&R

C

P1B7 (short)

HDNTYD

FKGSVYDADNDNT
YD
HDNTYD

P1B8

GKGADK

GKGADK

P1A8

GKGTEK

GKGTEK

GSLSGGNV
GSVELGGLFKSGT

GSLSGGNV
GSVELGGLFKSGT

MtrE loop 1
MtrE loop 2

C&R
C&R

QAGSLRGNGKYAGNHK

SLRGNGKYAG

C&R

EMYGWRSGDKIKAVKID
P
AAGAVNQHKNVGVYNR
Y
TAQAALGGTRTAGS

WRSGDKIKAV

Predicted to interact
with human Tf
Predicted to interact
with human Tf
Predicted to interact
with human Tf
Predicted to interact
with human Tf

NKAPKRYADFIRKYGKT
DGADGSF
YGKTDGADGSF

ADFIRKYGKT

C&R

GTLGPKVYDEYGEKISY
GGN
DGRTYTAAENGNNKSV
YSENAHKSTFTNE
KKPEDEIQ

KVYDEYGEKI

Prominently
displayed loop
Truncated version of
L4
Prominently
displayed loop
Prominently
displayed loop
Prominently
displayed loop

MtrE
MtrE1
MtrE2
TbpA
L3
L7
L11
Plug Loop
BamA
L4
L4 (Cterminus)
L6 (Cterminus)
L7
L8

VNQHKNVGVY
QAALGGTRTA

YGKTDGADGSF

NGNNKSVYSEN
KKPEDEIQ
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C&R
C&R
C&R
C&R

C&R
C&R
C&R

C&R
C&R
C&R
C&R

APPENDIX B
Table of Primers Used for Polymerase Chain Reaction
Antigen/loop

PCR forward primer sequence

PorB
P1A1
P1A3 (middle 10
amino acids)
P1A3 (Nterminus)
P1B5*
P1A5
P1A7
P1B7 (short)
P1B8
P1A8
MtrE
MtrE1
MtrE2

5’ CCCGACAATGGCGCGCATCATGGCGCGCAGGCGGATCGTGTGAAACCGGCG
ACGTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCCCGTGGGAAGGCAAAAGCTATTATCTGGGCGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTC GACAATGGCGGCCGCCTGAACAGCGTGCTGAAAGATACCGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCAAACTGGAATATTTTCATCAGGTGTATAGCCTGGGC
GACGTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCCGTCATAGCTATACCACCGAAAAACATGGCGACGTG
ACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCTTTAAAGGCAGCGTGTATGATGCGGATAACGATAAC
ACCTATGATGGCGACGTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCCATGATAATACCTATGATGGCGACGTGACTGTCGCC
CCA 3’
5’ CCCGACAATGGCGGCAAAGGCGCGGATAAGGCGACGTGACTGTCGCC
CCA 3’
5’ CCCGACAATGGCGGCAAAGGCACCGAAAAGGCGACGTGACTGTCGCC
CCA 3’
5’ CCCGACAATGGCGGCAGCCTGAGCGGTGGCAATGTGGGCGACGTGACTGTC
GCCCCA 3’
5’ CCCGACAATGGCGGCAGCGTGGAACTGGGCGGTCTGTTCAAAAGCGGCACC
GGCGACGTGACTGTCGCCCCA 3’

TbpA
L3
L7
L11
Plug loop

5’ CCCGTCGACAATGGCAGCCTGCGCGGCAACGGCAAATATGCGGGCGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCTGGCGCAGCGGCGATAAAATTAAAGCGGTGGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCGTGAACCAGCATAAAAACGTGGGCGTGTATGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCCAGGCGGCGCTGGGCGGCACCCGCACCGCGGGCGAC
GTGACTGTCGCCCCA 3’

BamA
L4
L4 (C-terminus)
L6 (C-terminus)
L7
L8

5’ CCCGTCGACAATGGCGCGGATTTTATTCGCAAATATGGCAAAACCGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCTATGGCAAAACCGATGGCGCGGATGGCAGCTTTGGC
GACGTGACTGTCGCCCCA
5’ CCCGTCGACAATGGCAAAGTGTATGATGAATATGGCGAAAAAATTGGCGAC
GTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCAACGGCAACAACAAAAGCGTGTATAGCGAAAACGGC
GACGTGACTGTCGCCCCA 3’
5’ CCCGTCGACAATGGCAAAAAACCGGAAGATGAAATTCAGGGCGACGTGACT
GTCGCCCCA 3’
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APPENDIX C
Mouse Sample Numbers Used for Imaging Flow Cytometry and SBA Assays
Mouse Sample
Numbers
13-17
32-34
45-49
55-59
64-67
68-72
88-92
103-107
123-127

Immunized Antigen

Assays Performed

Qβ-P1A5 (P1A5-C)
Qβ-BamA L4 C-terminus (BamA L4 C-term-C)
Qβ-TbpA L7 (TbpA L7-C)
Qβ-MtrE1 (MtrE1-C)
Qβ control (Negative control)
MS2-P1A5 (P1A5-R)
MS2-BamA L4 C-terminus (BamA L4 C-term-R)
MS2-TbpA L7 (TbpA L7-R)
MS2 control (Negative control)

Flow Cytometry & SBA
Flow Cytometry
Flow Cytometry & SBA
Flow Cytometry & SBA
Flow Cytometry & SBA
Flow Cytometry
Flow Cytometry & SBA
Flow Cytometry & SBA
Flow Cytometry & SBA
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